Editorial: the impact of the placebo effect in Crohn's disease

Bernstein, Çharles N.

doi:10.1111/apt.14036

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ese results support beneficial effects of ColonVita supplement on core GI symptoms in old adults with CGS. e significant placebo effect on the subjective GIQLI endpoints is in agreement with the recent review and metaanalysis of clinical trials that placebo intervention is associated with improvements in subjective clinical outcomes (response and remission) of gastrointestinal diseases, Evidence-Based Complementary and Alternative Medicine probably through the gut-brain interaction and a mechanism of enhanced healing expectation and conditioning [66][67][68][69].…”

Section: Discussionsupporting

confidence: 87%

The Relieving Effects of a Polyherb-Based Dietary Supplement ColonVita on Gastrointestinal Quality of Life Index (GIQLI) in Older Adults with Chronic Gastrointestinal Symptoms Are Influenced by Age and Cardiovascular Disease: A 12-Week Randomized Placebo-Controlled Trial

Xing

Zhang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Chronic gastrointestinal symptoms (CGS) negatively affect the quality of life in about 15–30% of the population without effective drugs. Recent studies suggest that dietary supplement may improve CGS, but inconsistent results exist. The goal of this study is to evaluate the effect of a polyherbal-based supplement ColonVita on the gastrointestinal quality of life index (GIQLI) in 100 old adults with CGS (63.1 ± 9.6 years) who were randomly assigned to daily ColonVita or placebo tablets (n = 50/group) for 12 weeks in a double-blind, randomized controlled trial design. No significant fibrdifferences were found between ColonVita and placebo in the baseline total GIQLI score (101.12 ± 16.87 vs. 101.80 ± 16.48) ( P > 0.05 ) or postintervention total GIQLI score (114.78 ± 9.62 vs. 111.74 ± 13.01) ( P > 0.05 ). However, ColonVita significantly improved 16 scores of the 19 core GI symptoms compared with 10 items improved by placebo. The ColonVita group significantly improved the remission rate of 5 core GI symptoms compared to placebo and significantly improved the total GIQLI scores (118.09 ± 7.88 vs. 109.50 ± 16.71) ( P < 0.05 ) and core GI symptom scores (64.61 ± 3.99 vs. 60.00 ± 8.65) ( P < 0.05 ) in people ≥60 years of age (n = 49) but not in those under 60 y (n = 51). ColonVita significantly improved the total GIQLI scores and core GI symptom scores in people without cardiovascular diseases (CVD) (n = 56) (116.74 ± 9.38 vs. 110.10 ± 14.28) ( P < 0.05 ) and (63.11 ± 4.53 vs. 59.93 ± 8.03) ( P = 0.07 ), respectively, but not in those with CVD (n = 44). Thus, ColonVita was beneficial for old adults with CGS, especially those ≥60 years of age and without CVD. Because a heterogenous pathogenesis of CGS-like irritable bowel syndrome (IBS) and inflammatory bowel disease (ISD) is differentially associated with CVD, different comorbidities may have influenced the outcomes of different trials that should be controlled in further studies.

show abstract

Section: Discussionsupporting

confidence: 87%

The Relieving Effects of a Polyherb-Based Dietary Supplement ColonVita on Gastrointestinal Quality of Life Index (GIQLI) in Older Adults with Chronic Gastrointestinal Symptoms Are Influenced by Age and Cardiovascular Disease: A 12-Week Randomized Placebo-Controlled Trial

Xing

Zhang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…The mechanism of this effect is unknown. However, recent studies have shown that in inflammatory bowel diseases, placebo effects, including remission and endoscopic response, are remarkable [52][53][54]. This effect could be attributed to the modulation of cytokine expression by the brain-gut axis, which would in-turn, downregulate the inflammatory response [55,56].…”

Section: Evaluation Of Infliximab As a Potential Therapeutics For Ulcmentioning

confidence: 99%

Transcriptome-Guided Drug Repositioning

et al. 2019

View full text Add to dashboard Cite

Drug repositioning can save considerable time and resources and significantly speed up the drug development process. The increasing availability of drug action and disease-associated transcriptome data makes it an attractive source for repositioning studies. Here, we have developed a transcriptome-guided approach for drug/biologics repositioning based on multi-layer self-organizing maps (ml-SOM). It allows for analyzing multiple transcriptome datasets by segmenting them into layers of drug action- and disease-associated transcriptome data. A comparison of expression changes in clusters of functionally related genes across the layers identifies “drug target” spots in disease layers and evaluates the repositioning possibility of a drug. The repositioning potential for two approved biologics drugs (infliximab and brodalumab) confirmed the drugs’ action for approved diseases (ulcerative colitis and Crohn’s disease for infliximab and psoriasis for brodalumab). We showed the potential efficacy of infliximab for the treatment of sarcoidosis, but not chronic obstructive pulmonary disease (COPD). Brodalumab failed to affect dysregulated functional gene clusters in Crohn’s disease (CD) and systemic juvenile idiopathic arthritis (SJIA), clearly indicating that it may not be effective in the treatment of these diseases. In conclusion, ml-SOM offers a novel approach for transcriptome-guided drug repositioning that could be particularly useful for biologics drugs.

show abstract

Placebo Effect on the Health-related Quality of Life of Inflammatory Bowel Disease Patients: A Systematic Review With Meta-analysis

Estevinho

Afonso

Rosa³

et al. 2018

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

show abstract

Editorial: the impact of the placebo effect in Crohn's disease

Abstract: Linked ContentThis article is linked to Jairath et al and Jairath, Feagan papers. To view these articles visit https://doi.org/10.1111/apt.13973 and https://doi.org/10.1111/apt.14074.

Cited by 4 publications

References 5 publications

The Relieving Effects of a Polyherb-Based Dietary Supplement ColonVita on Gastrointestinal Quality of Life Index (GIQLI) in Older Adults with Chronic Gastrointestinal Symptoms Are Influenced by Age and Cardiovascular Disease: A 12-Week Randomized Placebo-Controlled Trial

The Relieving Effects of a Polyherb-Based Dietary Supplement ColonVita on Gastrointestinal Quality of Life Index (GIQLI) in Older Adults with Chronic Gastrointestinal Symptoms Are Influenced by Age and Cardiovascular Disease: A 12-Week Randomized Placebo-Controlled Trial

Transcriptome-Guided Drug Repositioning

Placebo Effect on the Health-related Quality of Life of Inflammatory Bowel Disease Patients: A Systematic Review With Meta-analysis

Contact Info

Product

Resources

About